SCHEMBL3241607

SCHEMBL3241607

CCN([CH]Cc1ccccc1)CC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.48
TP53 P04637 1/20 0.44
TSHR P16473 3/20 0.42
KCNH2 Q12809 3/20 0.41
AOC3 Q16853 2/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
CHRM1 P11229 1/20 0.41
DRD1 P21728 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MGLL Q99685 1/20 0.40
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6668054 0.78 MAOB (0.56) MAOBTP53TSHRKCNH2AOC3
SCHEMBL3814043 0.78 KCNH2 (0.46) KCNH2AOC3SLC6A2SLC6A4SLC6A3
SCHEMBL315074 0.76 MAOB (0.52) MAOBTP53TSHRKCNH2AOC3
SCHEMBL8084896 0.73 MAOB (0.48) MAOBTP53TSHRKCNH2AOC3
SCHEMBL5831023 0.70 MAOB (0.50) MAOBTP53TSHRKCNH2ALDH1A1
SCHEMBL968495 0.70 LMNA (0.48) TP53TSHRAOC3ALDH1A1MGLL
SCHEMBL11821323 0.70 TSHR (0.48) TP53TSHRKCNH2AOC3CHRM2
SCHEMBL8415458 0.70 TSHR (0.48) MAOBTP53TSHRKCNH2AOC3
SCHEMBL2727275 0.70 KCNH2 (0.50) MAOBTP53TSHRKCNH2AOC3
Allylbenzene SCHEMBL997693 0.70 KCNH2 (0.47) MAOBTP53TSHRKCNH2AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
CN-1148007-A Multi-layer polyamide film TOYO BOSEKI (JP) 1997-04-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 MAOB 860/4885TP53 1085/4885TSHR 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.